Results 1 to 10 of about 12,817 (217)

Multiscale Modeling of an 8‐Week Combination Regimen of Bemnifosbuvir and Ruzasvir in Patients with Chronic Hepatitis C Virus Infection [PDF]

Clinical Pharmacology &Therapeutics, EarlyView.
Bemnifosbuvir (BEM) and ruzasvir (RZR) are pan‐genotypic HCV polymerase (NS5B) and NS5A inhibitors, respectively. In a single‐arm study (NCT05904470), 215 treatment‐naïve, adherent participants with chronic HCV (with or without cirrhosis) received BEM 550 mg QD plus RZR 180 mg QD for 8 weeks.
Carolin Zitzmann, Ruy M. Ribeiro, Aurelien Marc, Xiao‐Jian Zhou, Alan S. Perelson   +4 more
wiley   +2 more sources

Development of a Machine Learning Model to Predict Short Duration HCV Treatment Response [PDF]

Journal of Viral Hepatitis, Volume 33, Issue 10, October 2026.
ABSTRACT Standard durations of direct acting antivirals (DAAs; 8–12 weeks) can be a barrier to HCV treatment initiation and completion among marginalized populations. This study developed and internally validated a machine learning model to predict short‐duration (4–6 weeks) DAA response using baseline clinical factors with potential to improve ...
Joanne M. Carson, Sebastiano Barbieri, Andrey Verich, Elise Tu, Andrew Lloyd, Gregory J. Dore, Gail V. Matthews, Marianne Martinello   +7 more
wiley   +2 more sources

Design and Synthesis of Novel Imidazo[4,5‐c]pyridine Derivatives, Evaluation of Their Activity Against Hepatitis C Virus and In Silico Prediction of Their Binding Mode to NS4B Protein [PDF]

ChemMedChem, Volume 21, Issue 13, 14 July 2026.
A series of 18 novel imidazo[4,5‐c]pyridines was synthesized, and their anti‐HCV activity was evaluated. Compound 30b was identified as the most promising one, with EC50 = 6.61 µM. Molecular docking studies indicated the NS4B protein of the HCV as a potential target of these derivatives.
Eftychia Karampella, George Mpekoulis, Maria Georgiou, Iris Kolida, Katerina I. Kalliampakou, Eirini P. Kollia, Eleni V. Mikropoulou, Maria Halabalaki, Christos T. Chasapis, Niki Vassilaki, Nikolaos Lougiakis   +10 more
wiley   +2 more sources

A novel dimerization site in non-structural protein 5A of hepatitis C virus regulates viral replication fitness. [PDF]

PLoS Pathogens
We previously found that high genome replication fitness of the hepatitis C virus (HCV) was associated with severe disease in immunocompromised patients.
Paul Rothhaar, Thibault Tubiana, Colin Förster, Gabriel Vanegas Arias, Tomke Arand, Noemi Schäfer, Philipp Ralfs, Christian Heuss, Antonio Piras, Andreas Pichlmair, Xavier Hanoulle, Stéphane Bressanelli, Volker Lohmann   +12 more
doaj   +2 more sources

Hepatitis C Virus Infection in the PERSIAN Guilan Cohort Study Population: Intrafamilial Transmission Incidence and Response to SOVODAK‐Based Therapy [PDF]

Health Science Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background Hepatitis C virus (HCV) infection is one of the leading causes of liver‐related diseases such as cirrhosis and hepatocellular carcinoma. Despite ongoing efforts, no effective vaccine has been developed to date due to the virus's high mutation rate and extensive genetic variability. This study aimed to determine the prevalence of HCV
Farahnaz Joukar, Sara Yeganeh, Narges Eslami, Fariborz Mansour‐Ghanaei   +3 more
wiley   +2 more sources

Hepatitis C Virus and Type 2 Diabetes: Mechanisms, Clinical Impact, and Post‐DAA Management [PDF]

Journal of Medical Virology, Volume 98, Issue 5, May 2026.
ABSTRACT Hepatitis C virus (HCV) infection remains a major global health burden despite advances in direct‐acting antiviral (DAA) therapies. Beyond hepatic complications such as cirrhosis and hepatocellular carcinoma (HCC), HCV has been strongly linked to metabolic disorders, particularly type 2 diabetes mellitus (T2DM).
Shen‐Shong Chang, Ching‐Hsuan Liu, Shu‐Yen Chan, Liang‐Tzung Lin   +3 more
wiley   +2 more sources

A key role for hepatitis C virus NS5A serine 225 phosphorylation revealed by super-resolution microscopy [PDF]

Scientific Reports
NS5A is a multi-functional phosphoprotein that plays a key role in hepatitis C virus (HCV) genome replication and assembly. The consequences of NS5A phosphorylation for HCV biology remain largely undefined. We previously identified serine 225 (S225) as a
Niluka Goonawardane, Chunhong Yin, Grace C Roberts, Carsten Zothner, Mark Harris   +4 more
doaj   +2 more sources

MxB Disrupts Hepatitis C Virus NS5A–CypA Complex: Insights From a Combined Theoretical and Experimental Approach

Frontiers in Microbiology, 2022
The human myxovirus resistance B (MxB) protein is an interferon-induced restriction factor that fights a wide range of viruses. We previously demonstrated that MxB binds to hepatitis C virus (HCV)-encoded non-structural protein 5A (NS5A) and inhibits HCV
Quanjie Li, Ni An, Xiao Yin, Xiao Yin, Ruixin Zhang, Huihan Shao, Dongrong Yi, Shan Cen   +7 more
doaj   +1 more source

Identification of novel neutralizing determinants for protection against HCV

Hepatology, EarlyView., 2022
Identification of novel neutralizing determinants for protection against hepatitis C virus. Abstract Background and Aims HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine.
Garazi P. Alzua, Anne F. Pihl, Anna Offersgaard, Rodrigo Velázquez‐Moctezuma, Carlos R. Duarte Hernandez, Elias H. Augestad, Ulrik Fahnøe, Christian K. Mathiesen, Henrik Krarup, Mansun Law, Jannick Prentoe, Jens Bukh, Judith M. Gottwein   +12 more
wiley   +1 more source

Hepatitis C virus NS5A protein promotes the lysosomal degradation of diacylglycerol O-acyltransferase 1 (DGAT1) via endosomal microautophagy

Autophagy Reports, 2022
Many viruses often use a protein degradation system (e.g., the ubiquitin-proteasome pathway or lysosome pathway) to modulate viral propagation and viral pathogenesis.
Putu Yuliandari, Chieko Matsui, Lin Deng, Takayuki Abe, Hiroyuki Mori, Shuhei Taguwa, Chikako Ono, Takasuke Fukuhara, Yoshiharu Matsuura, Ikuo Shoji   +9 more
doaj   +1 more source